07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat psoriasis and...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

Beteflam Patch regulatory update

Health Canada accepted for review an NDS for Beteflam Patch from Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR, Mississauga, Ontario) to treat inflammatory skin conditions, including chronic plaque psoriasis. The company said it expects a decision at...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Cipher, Institut Biochimique sales and marketing update

Cipher received exclusive Canadian rights to market Institut's Betesil Patch to treat inflammatory skin conditions, including plaque psoriasis. The self-adhesive medicated plaster containing 0.1% betamethasone valerate is already marketed in the U.K., France, Greece, Hungary...